Karin Tyburski

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

Ursula A. Matulonis, Suzanne Berlin, Percy Ivy et al. · Journal of Clinical Oncology · 2009 · 301 citations · Full text

Medicine, Oncology, Pharmacology +11

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

Joyce F. Liu, Sara M. Tolaney, Michael J. Birrer et al. · European Journal of Cancer · 2013 · 172 citations · Full text

Medicine, Oncology, Pharmacology +17

Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor

Emily Robinson, Ursula A. Matulonis, Percy Ivy et al. · Clinical Journal of the American Society of Nephrology · 2010 · 87 citations

Medicine, Oncology, Pharmacotherapy +14

A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma

Susana M. Campos, Richard T. Penson, Ursula A. Matulonis et al. · Gynecologic Oncology · 2012 · 49 citations

Medicine, Gynecology, Oncology +14

Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer

Ursula A. Matulonis, Suzanne Berlin, Carolyn Krasner et al. · Journal of Clinical Oncology · 2008 · 33 citations

Medicine, Pharmacology, Pharmacotherapy +17